Presented in 'State of the Art and Featured Research Session' at the
2014 European Society of Cardiology Congress
TSX Exchange Symbol: RVX
BARCELONA, Spain and CALGARY, AB, Sept. 2, 2014 /CNW/ - Resverlogix
Corp. (TSX: RVX) announced today that Dr. Jan Johansson, senior vice
president of medical affairs at Resverlogix delivered an oral
presentation at the 2014 European Society of Cardiology (ESC) Congress
in Barcelona, Spain. In his presentation, entitled: 'Effects of RVX-208 on MACE, ApoA-I and HDLs; a post-hoc analysis from
the pooled SUSTAIN and ASSURE clinical trials', Dr. Johansson reported that patients with cardiovascular disease
(CVD) arising from atherosclerosis when given RVX-208 had a 55%
(p=0.02) relative risk reduction (RRR) in MACE. More importantly, this
beneficial effect of RVX-208 on patients with diabetes mellitus was
accentuated with a RRR in MACE that was lowered by 77% (p=0.01). These
observed reductions in MACE may stem from the ability of RVX-208 to
significantly improve specific biomarkers of CVD risk measured in the
SUSTAIN and ASSURE trials, including: higher levels of ApoA-I protein
(p<0.01), an increase in HDL-C (p<0.001), more large HDL-particles
(p<0.05) and growth in HDL particle size (p<0.05). The significant
improvement in these biomarkers was in treated patients vs. placebo,
which point to the beneficial effects of RVX-208 on reverse cholesterol
transport.
RVX-208 acts via an epigenetic pathway and it is the first selective BET
inhibitor being studied for treatment of CVD. The new information
contained in the ESC presentation arose from the analysis of data
pooled from the ASSURE and SUSTAIN clinical trials.
"The above findings are valuable to Resverlogix because they put the
company in an advantageous position in the emerging field of
therapeutics based on BET inhibition," said Dr. Norman C.W. Wong, chief
scientific officer of Resverlogix and also a practicing
endocrinologist. "The data enhances the potential for RVX-208 to lower
MACE in CVD patients and especially in those with diabetes mellitus.
These key pieces of information will be used for the design of our next
clinical trial that will continue the development of RVX-208 towards
product registration."
Donald McCaffrey, president and chief executive officer of Resverlogix
added, "We are very pleased to have this data highlighted at the ESC
Congress. It underscores our plans to diversify the development of
RVX-208 by studying its activity in additional indications. Moving
forward, in addition to the clinical paths in cardiovascular disease,
diabetes mellitus and Alzheimer's Disease, we are exploring other
indications pertaining to chronic kidney disease (CKD), nonalcoholic
steatohepatitis (NASH) and human immunodeficiency virus (HIV)
lipodystrophy."
About RVX-208
RVX-208 is a first-in-class small molecule that selectively inhibits BET
bromodomains. RVX-208 functions via several mechanisms such as removing
atherosclerotic plaque via reverse cholesterol transport (RCT), the
natural process through which atherosclerotic plaque is transported out
of the arteries and then removed from the body by the liver. RVX-208
increases production of Apolipoprotein A-I (ApoA-I), the key building
block of functional high-density lipoprotein (HDL) particles and the type required for RCT.
These newly produced, functional HDL particles are flat and empty and
can efficiently remove plaque and stabilize or reverse atherosclerotic
disease. Analysis of recent clinical trials data showed that RVX-208
significantly reduces coronary atherosclerosis and major adverse
cardiac events in patients with CVD who have a low level of HDL and
elevated hsCRP, a population with unmet medical need. ApoA-I
enhancement and glucose lowering have been reported to exert beneficial
effects in Alzheimer's disease and diabetes mellitus, respectively.
RVX-208 also has anti-inflammatory effects including effects on
Interleukin-6 inhibition, vascular cell adhesion-1 and monocyte
chemotactic protein-1, factors known to be involved in atherosclerosis
and plaque stability.
About Resverlogix
Resverlogix Corp. (TSX: RVX) is a clinical stage cardiovascular company
developing compounds involving a therapeutic increase in ApoA-I.
RVX-208 is a first-in-class small molecule for the treatment of
atherosclerosis and other chronic diseases such as Diabetes Mellitus
and Alzheimer's disease. RVX-208 is the first BET bromodomain inhibitor
in clinical trials. Resverlogix's common shares trade on the Toronto
Stock Exchange (TSX: RVX). For further information please visit www.resverlogix.com. We can be followed on our blog at http://www.resverlogix.com/blog.
This news release may contain certain forward-looking information as
defined under applicable Canadian securities legislation, that are not
based on historical fact, including without limitation statements
containing the words "believes", "anticipates", "plans", "intends",
"will", "should", "expects", "continue", "estimate", "forecasts" and
other similar expressions. In particular, this news release includes
forward looking information relating to research and development
activities and the potential role of RVX-208 in the treatment of
atherosclerosis. Our actual results, events or developments could be
materially different from those expressed or implied by these
forward-looking statements. We can give no assurance that any of the
events or expectations will occur or be realized. By their nature,
forward-looking statements are subject to numerous assumptions and risk
factors including but not limited to those associated with the success
of research and development programs, clinical trial programs including
possible delays in patient recruitment, the regulatory approval
process, competition, securing and maintaining corporate alliances,
market acceptance of the Company's products, the availability of
government and insurance reimbursements for the Company's products, the
strength of intellectual property, financing capability, the potential
dilutive effects of any financing, reliance on subcontractors and key
personnel and additional assumptions and risk factors discussed in our
Annual Information Form and most recent MD&A which are incorporated
herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are
expressly qualified by this cautionary statement and are made as of the
date hereof. The Company disclaims any intention and has no obligation
or responsibility, except as required by law, to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
SOURCE Resverlogix Corp.
